MediWound Says FDA Accepted For Review The Supplement To The NexoBrid BLA To Include Pediatric Patients With Severe Thermal Burns
Portfolio Pulse from Benzinga Newsdesk
MediWound announced that the FDA has accepted for review the supplement to the NexoBrid Biologics License Application (BLA) to include treatment for pediatric patients with severe thermal burns. This acceptance could potentially expand the use of NexoBrid to a broader patient population.
January 09, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's acceptance for review of MediWound's BLA supplement for NexoBrid to include pediatric patients could lead to an expanded market for the product if approved.
The FDA's acceptance of the BLA supplement is a positive regulatory step for MediWound, indicating progress towards potential approval. If the supplement is approved, it would allow NexoBrid to be used in pediatric patients, thus expanding the product's market and potentially increasing the company's revenue. This news is likely to be viewed positively by investors and could lead to a short-term increase in MediWound's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100